SNDX

Syndax Pharmaceuticals, Inc. (SNDX) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Growth Runway

High gross margin profile suggests the core asset can scale if commercialization improves.

Revenue base remains relatively small versus enterprise value, leaving room for multi-year expansion if pipeline execution holds.

Profitability

TTM margins remain deeply negative, with EBIT margin at -53.7% and net profit margin at -87.6%.

Return on equity and return on invested capital are both materially negative, indicating the business is still far from durable profitability.

Financial Health

Liquidity is strong, with a current ratio of 6.8 and cash ratio of 3.4.

Balance sheet leverage is elevated, but net debt remains manageable relative to the company’s cash position.

Valuation

The stock trades at a rich EV/Sales multiple near 7.9x, which assumes meaningful future growth.

Negative earnings and free cash flow keep traditional earnings-based valuation metrics unhelpful, but the cash-rich balance sheet limits near-term distress risk.

Execution Risk

Operating losses and negative cash flow create ongoing execution risk until the company proves sustainable commercial traction.

High leverage and weak coverage ratios increase sensitivity to any slowdown in growth or funding needs.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Syndax Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →